Difference between revisions of "MDM2"
Jump to navigation
Jump to search
(create) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
*[[Liposarcoma]]. | *[[Liposarcoma]]. | ||
Aberrant positives: | |||
* | *[[Fat necrosis]]. | ||
*[[Angiomyolipoma]].<ref name=pmid27369456>{{Cite journal | last1 = Asch-Kendrick | first1 = RJ. | last2 = Shetty | first2 = S. | last3 = Goldblum | first3 = JR. | last4 = Sharma | first4 = R. | last5 = Epstein | first5 = JI. | last6 = Argani | first6 = P. | last7 = Cimino-Mathews | first7 = A. | title = A subset of fat-predominant angiomyolipomas label for MDM2: a potential diagnostic pitfall. | journal = Hum Pathol | volume = 57 | issue = | pages = 7-12 | month = Nov | year = 2016 | doi = 10.1016/j.humpath.2016.06.014 | PMID = 27369456 }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 17:26, 5 March 2017
MDM2 is an immunostain used in soft tissue pathology.
Positive
Aberrant positives:
References
- ↑ Asch-Kendrick, RJ.; Shetty, S.; Goldblum, JR.; Sharma, R.; Epstein, JI.; Argani, P.; Cimino-Mathews, A. (Nov 2016). "A subset of fat-predominant angiomyolipomas label for MDM2: a potential diagnostic pitfall.". Hum Pathol 57: 7-12. doi:10.1016/j.humpath.2016.06.014. PMID 27369456.